SAR408701

DRUG4 trials

Sponsors

Sanofi

Conditions

Neoplasm MalignantNon-small Cell Lung Cancer Metastatic

Phase 1

Evaluation of SAR408701 in Patients With Advanced Solid Tumors

TerminatedNCT02187848

SanofiNeoplasm Malignant

Start: 2014-07-23End: 2024-11-19Updated: 2025-02-10

Evaluation of SAR408701 in Japanese Patients With Advanced Malignant Solid Tumors

CompletedNCT03324113

SanofiNeoplasm Malignant

Start: 2017-10-17End: 2022-12-26Updated: 2025-08-05

Phase 2

Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Pretreated Patients With NSQ NSCLC (CARMEN-LC04)

TerminatedNCT04394624

SanofiNon-small Cell Lung Cancer Metastatic

Start: 2020-08-31End: 2024-10-24Updated: 2025-06-06

Phase 3

SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients

Active, not recruitingNCT04154956

SanofiNon-small Cell Lung Cancer Metastatic

Start: 2020-02-06End: 2026-03-31Updated: 2025-08-05

Related Papers

Biomarker analysis from a Phase 1/1b study of tusamitamab ravtansine in patients with advanced non-small cell lung cancer.

2025-12-03

Evaluation of the Safety, Pharmacokinetics, and Antitumor Activity of Tusamitamab Ravtansine in Patients With Nonsquamous NSCLC With High or Moderate Expression of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5.

2025-05-15

Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens

Cancer Research Communications2023-08-0311 citations

Phase 1/2 study of tusamitamab ravtansine in patients with advanced solid tumors: Pooled safety analysis of corneal adverse events.

Journal of Clinical Oncology2023-06-012 citations

Abstract CT213: Biomarker analysis from Phase 1/2 study of tusamitamab ravtansine (SAR408701) in patients with advanced non-small cell lung cancer (NSCLC)

Cancer Research2023-04-14

Safety and efficacy of tusamitamab ravtansine (SAR408701) in long-term treated patients with nonsquamous non–small cell lung cancer (NSQ NSCLC) expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5).

Journal of Clinical Oncology2022-06-0126 citations

Efficacy and safety of the antibody-drug conjugate (ADC) SAR408701 in patients (pts) with non-squamous non-small cell lung cancer (NSQ NSCLC) expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5).

Journal of Clinical Oncology2020-05-2038 citations

Phase III trial comparing antibody-drug conjugate (ADC) SAR408701 with docetaxel in patients with metastatic non-squamous non-small cell lung cancer (NSQ NSCLC) failing chemotherapy and immunotherapy.

Journal of Clinical Oncology2020-05-2011 citations

Antibodies to watch in 2020.

2020-01-01328 citations

First-in-human phase 1 study of the antibody-drug conjugate (ADC) SAR408701 in advanced solid tumors: Dose-expansion cohort of patients (pts) with non-squamous non-small cell lung cancer (NSQ NSCLC).

Journal of Clinical Oncology2019-05-204 citations